Long COVID, ME/CFS, fibromyalgia, mold-related illness, MCAS — different labels, shared underlying biology. Persistent immune dysregulation, mitochondrial dysfunction, and unresolved inflammation are the targets that regenerative medicine engages directly.
By Jed Ryan, Founder and CEO · Reviewed by Adas Darinskas, PhD, Chief Science Officer · Published · Last reviewed
“Chronic illness” here refers to the cluster of conditions that defy single-system explanation: post-viral syndromes, persistent immune dysregulation, mitochondrial-driven fatigue, mast cell over-activation, and the multi-system collapse that often follows them. Patients in this category have usually seen many specialists, accumulated many partial labels, and been told repeatedly that nothing is wrong — despite knowing, viscerally, that something is.
We work with the following in this cluster:
These look unrelated diagnostically. Underneath, they share the same biological signature — and that’s the level at which a regenerative protocol can do useful work.
Across the chronic-illness cluster, five interlocking systems tend to be dysfunctional simultaneously. The reason these conditions are so hard to treat conventionally is that addressing any one in isolation rarely helps — the others pull the patient back toward dysfunction.
Conventional care addresses these one at a time — antimicrobials for infection, anti-inflammatories for inflammation, supplements for mitochondria. Regenerative medicine addresses them at the cellular level all at once.
Four primary mechanisms do most of the work in regenerative protocols for this cluster.
The framing is mechanistic. We don’t promise outcomes — chronic illness is too heterogeneous for that. We describe what these therapies do at the cellular level and let patients evaluate whether the biology lines up with what they’re experiencing.
Each protocol is designed individually by Dr. Adas Darinskas based on the specific diagnosis, history, and exposure profile. The four building blocks below are the ones most often deployed for chronic-illness cases.
An advanced class of mesenchymal stem cells with a stress-enduring property — they survive the inflammatory, oxidative, hypoxic environments characteristic of chronic illness, where conventional MSCs often die before they can work. Delivered systemically by IV. Mitochondrial transfer is one of their most directly relevant actions in this cluster.
Learn moreStem-cell-derived nanoparticles that carry the regenerative messaging without the cells themselves. They distribute systemically by IV and reach tissue beds that are difficult to dose with cellular therapy directly. Particularly useful for the broad multi-system inflammation that defines this cluster.
Learn moreA targeted peptide stack: BPC-157 and KPV for gut barrier and inflammation; Thymosin Alpha-1 for immune balance; MOTS-c and SS-31 for mitochondrial bioenergetics specifically. The exact combination is built to the case — not every patient gets every peptide.
Learn moreNAD+ infusions directly support the mitochondrial cofactor pool that’s depleted in chronic illness. Vitamin C, glutathione, and amino-acid IVs underwrite the broader metabolic and antioxidant load. Often layered through the days surrounding cellular therapy.
Learn moreMost chronic-illness protocols layer these — systemic MSC and exosome IV, peptide stack continuing at home, and high-dose metabolic IVs underwriting the bioenergetic and antioxidant capacity. Many patients return at 3–6 months for additional cellular dosing because the underlying biology takes time to shift.
The chronic-illness cluster is not monolithic. Evidence quality varies, mechanism varies, and what’s reasonable to expect varies. Here’s where the science currently sits for the conditions we see most often.
Long COVID is the most-studied post-viral syndrome of the modern era and shares deep biological overlap with the rest of this cluster — persistent immune activation, mitochondrial dysfunction, and microvascular disturbance. Mechanistically, the targets are the lingering inflammatory environment, the metabolic deficit, and the endothelial damage that drives many of the systemic symptoms.
MSC and exosome research in Long COVID is advancing rapidly through preclinical and early-phase clinical work. We coordinate cases with realistic framing about response variability, and we layer the cellular work with peptide and metabolic support designed for the post-viral context specifically.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome is the prototype of mitochondrial-dominated chronic illness. Post-exertional malaise, the hallmark feature, reflects an inability of mitochondria to recover after stress — not deconditioning, not psychological, a measurable cellular phenotype.
The regenerative approach targets mitochondrial bioenergetics directly through MSC mitochondrial transfer, MOTS-c and SS-31 peptides, and high-dose NAD+ infusions, layered with immune recalibration via MSC and exosome therapy. We’re explicit with patients that ME/CFS responds heterogeneously and that protocols need careful pacing.
Mycotoxin exposure and mast cell activation syndrome often co-occur and share an immunological signature: a hypersensitive, hyperreactive immune system stuck in a state of constant low-grade activation. Standard care focuses on antihistamines and avoidance — necessary but often insufficient.
Regenerative protocols in this cluster aim to recalibrate immune reactivity through MSC and exosome therapy, support gut barrier integrity through targeted peptides (BPC-157, KPV), and rebuild the metabolic capacity that’s been depleted by chronic immune activation. Clinical evidence is at an earlier stage than the post-viral data, but the mechanistic case is strong.
In every case the conversation starts with what’s known, what’s emerging, and what reasonable expectations look like. We don’t pitch outcomes. We describe mechanisms and let the evidence speak for itself.
Strong Craft Regen maintains a continuously updated repository of peer-reviewed research on regenerative medicine — the studies, mechanisms, and ongoing investigations that inform every protocol we coordinate.
Explore the research →